Cabazitaxel
- Generic Name
- Cabazitaxel
- Brand Names
- Jevtana, Cabazitaxel Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C45H57NO14
- CAS Number
- 183133-96-2
- Unique Ingredient Identifier
- 51F690397J
- Background
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like paclitaxel and docetaxel.
Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
- Indication
用于治疗转移性去势抵抗性前列腺癌患者。
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase I/II Cabazitaxel for Recurrent Malignant Glioma
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT01740570
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Conditions
- Prostate Cancer Metastatic
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 63
- Registration Number
- NCT01718353
- Locations
- 🇺🇸
Investigational Site Number 840017, Rockville, Maryland, United States
🇺🇸Investigational Site Number 840003, Birmingham, Alabama, United States
🇺🇸Investigational Site Number 840002, Baltimore, Maryland, United States
Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 84
- Registration Number
- NCT01693549
- Locations
- 🇬🇷
2nd Dept of Medical Oncology, Metropolitan Hospital, Athens, Greece
🇬🇷2nd Dept of Medical Oncology, Agios Savvas Cancer Hospital, Athens, Greece
🇬🇷Dept of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel
- Conditions
- Transitional Cell Carcinoma
- Interventions
- Other: Best Supportive Care
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Dr Anjali Zarkar
- Target Recruit Count
- 20
- Registration Number
- NCT01668459
- Locations
- 🇬🇧
University Hospitals Birmingham, Birmingham, United Kingdom
Cabazitaxel and Radiation For Patients With Prostate Cancer
- First Posted Date
- 2012-07-26
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Brown University
- Target Recruit Count
- 5
- Registration Number
- NCT01650285
- Locations
- 🇺🇸
Miriam Hospital, Providence, Rhode Island, United States
Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 45
- Registration Number
- NCT01649635
- Locations
- 🇧🇷
Investigational Site Number 006, Lajeado, Brazil
🇧🇷Investigational Site Number 005, Porto Alegre, Brazil
🇧🇷Investigational Site Number 002, São Paulo, Brazil
A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes
- Conditions
- Recurrent Head and Neck CancerMetastatic Head and Neck Cancer
- Interventions
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 31
- Registration Number
- NCT01620242
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷Centre Léon Berard, Lyon, France
🇫🇷Centre Antoine Lacassagne, Nice, France
Bristol Bladder Trial
- Conditions
- Infiltrating Bladder Urothelial Carcinoma
- Interventions
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2020-11-13
- Target Recruit Count
- 28
- Registration Number
- NCT01616875
- Locations
- 🇬🇧
Bristol Haematology + Oncology Centre, Horfield Road, Bristol, United Kingdom
A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 19
- Registration Number
- NCT01600339
- Locations
- 🇮🇱
Rambam MC, Haifa, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Rahul Aggarwal
- Target Recruit Count
- 25
- Registration Number
- NCT01594918
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸UCSF Comprehensive Cancer Center, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.